1,106 material Form 8-K filings that 909 companies we cover made with the SEC in June 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
HeartBeam said CEO Robert Eno agreed to leave as CEO and board member effective June 30, 2026, as part of a strategic reorganization. Founder and President Branislav Vajdic will become principal executive officer effective July 1, 2026, and the company said it will license its 3D ECG technology to established partners rather than rely only on direct medical device sales. Shareholders face a leadership transition and a change in business model, and the filing gives no financial results for the period.
Robert Eno's departure as CEO, board member and principal executive officer is effective June 30, 2026; he is expected to enter a consulting agreement.
Branislav Vajdic, Ph.D., becomes principal executive officer effective July 1, 2026; Rich Ferrari, Executive Chairman, co-leads the implementation teams.
Mark Strome resigned from the board and all committees effective immediately, as notified on June 18, 2026.
The company will provide more details on its strategy on its Second Quarter 2026 conference call in August.
Texas Ventures Acquisition IV Corp, a blank check company, closed its initial public offering of 17,250,000 units at $10.00 per unit on June 22, 2026, including full exercise of the over-allotment option, for gross proceeds of $172,500,000. Of the proceeds and private placement, $173,362,500 was placed in a trust account, to be released only upon a business combination, certain shareholder votes, or redemption if no combination is completed within 18 months.
17,250,000 units sold at $10.00 each, for gross proceeds of $172,500,000 on June 22, 2026
$173,362,500, or $10.05 per unit, placed in trust; funds stay there until a business combination or redemption
Private placement of 6,100,000 warrants at $1.00 each ($6,100,000) to the Sponsor and Cohen & Company Capital Markets
Company has 18 months from the IPO closing to complete an initial business combination
GD Culture Group agreed on June 24, 2026 to sell 259,301,306 shares of common stock at $0.021 per share in a registered direct offering, with about $5.45 million in gross proceeds before fees and expenses. The same day, the company disclosed that on June 22, 2026 it received a Nasdaq notice that its stock closed below $1.00 for 30 consecutive business days, and it has until December 21, 2026 to regain compliance.
259,301,306 shares sold at $0.021 per share, for about $5.45 million in gross proceeds
Placement agent Univest Securities, LLC is paid a cash fee of 7.0% of gross proceeds, plus expenses up to $50,000
Nasdaq notice dated June 22, 2026 cites a minimum bid price deficiency; the company has until December 21, 2026 to regain compliance
Company may consider a reverse stock split to regain compliance; shares continue to trade as GDC
Morgan Stanley said its Board will raise the quarterly common stock dividend to $1.15 per share from $1.00, starting with the dividend expected to be declared in the third quarter of 2026, and reauthorized a multi-year share repurchase program of up to $20 billion with no set expiration date. The Federal Reserve's 2026 stress test results do not change the firm's 4.3% Stress Capital Buffer requirement, which the firm expects to remain in place until October 1, 2027.
Quarterly dividend rises 15 cents, from $1.00 to $1.15 per share, starting with the third quarter of 2026 declaration.
Share repurchase program of up to $20 billion reauthorized, beginning in the third quarter of 2026, with no set expiration date.
Stress Capital Buffer requirement stays at 4.3%; the firm's aggregate U.S. Basel III CET1 ratio is 11.8%, versus 15.1% as of March 31, 2026.
Goldman Sachs said the Federal Reserve released its 2026 Comprehensive Capital Analysis and Review results and that the firm remains well capitalized. The firm intends to raise its common dividend from $4.50 to $5.00 per share starting July 1, 2026, subject to Board approval at its scheduled third quarter meeting.
Planned dividend rise from $4.50 to $5.00 per share, effective July 1, 2026, subject to Board approval at the third quarter meeting
Dividend increase is 11% above current levels and 25% above the prior year, per the filing
Stress capital buffer stays at 3.4% through September 30, 2027; CET1 requirement stays at 11.4%
Jefferies reported net earnings attributable to common shareholders of $226 million, or $1.02 per diluted share, for the quarter ended May 31, 2026, up from $88 million, or $0.40 per share, a year earlier. Net revenues rose to $2.21 billion from $1.63 billion, led by investment banking and a record quarter for Equities, and the board raised the share buyback authorization to $250 million. The figures are preliminary and may be revised in the Form 10-Q the company expects to file on or about July 9, 2026.
Net revenues of $2.21 billion, compared with $1.63 billion in the prior-year quarter
Investment banking net revenues of $1.21 billion, up 57% from the prior-year quarter; Equities net revenues a record $601 million, up 14%
Repurchased 4.0 million shares for $197 million during the quarter; board raised buyback authorization to $250 million
Quarterly cash dividend of $0.40 per share, payable August 28, 2026 to holders of record on August 18, 2026
Elastic N.V. committed on June 23, 2026 to a plan to reduce its workforce by about 7%, with total non-recurring cash charges of approximately $22 million to $25 million, mostly employee severance, and most of those charges expected in the first quarter of fiscal 2027. Chief Product Officer Ken Exner also resigned, with his last day set for July 17, 2026, and senior engineering leaders will now report to CEO Ashutosh Kulkarni. The filing says total headcount is still expected to grow this fiscal year.
Workforce reduction of approximately 7%; implementation expected to be substantially complete by the end of fiscal Q3 2027
Non-recurring cash charges of approximately $22 million to $25 million, mostly severance and termination benefits
Chief Product Officer Ken Exner resigns effective July 17, 2026; he is leaving for another opportunity, not over a disagreement
Engineering leaders for Elasticsearch and Platform Group and Observability and Security Group will report to CEO Ashutosh Kulkarni
On June 24, 2026, Passage Bio agreed to merge with Remix Therapeutics in an all-stock deal, with the combined company to operate as Remix Therapeutics under the ticker RMTX. Passage shareholders are expected to own about 7% of the combined company, subject to adjustment based on Passage's net cash at closing, and will receive contingent value rights tied to milestones from its out-licensed pediatric gene therapy assets. Closing requires stockholder approvals and a concurrent Remix financing of at least $100 million, and is expected in the fourth quarter of 2026.
Remix has been ascribed an aggregate equity value of $226 million; Passage's equity value is expected to be about $20 million, subject to net cash adjustment.
Remix will complete a concurrent financing of at least $100 million immediately before the merger closes.
Termination payments: $17.5 million from Remix to Passage, or $1.548 million from Passage to Remix, in specified circumstances.
Peter Smith, Ph.D., Remix's co-founder and CEO, will become CEO of the combined company; the merger outside date is December 24, 2026.
MillerKnoll reported fourth-quarter and full fiscal 2026 results for the period ended May 30, 2026, with net sales up 4.4% to $1.004 billion and GAAP diluted EPS of $0.34, compared with a loss of $0.84 a year earlier. Adjusted diluted EPS fell to $0.55 from $0.60, orders declined 6.3%, and Jeff Stutz, Chief Operating Officer, is stepping into the interim CEO role. The company also gave first-quarter and full fiscal 2027 adjusted EPS outlooks of $0.33 to $0.39 and $1.85 to $2.15.
Q4 net sales of $1.004 billion, up 4.4% as reported; orders of $971.5 million, down 6.3%
Q4 GAAP diluted EPS of $0.34 vs. a loss of $0.84 a year earlier; adjusted diluted EPS of $0.55 vs. $0.60
Q1 FY2027 adjusted EPS outlook of $0.33 to $0.39; full year FY2027 outlook of $1.85 to $2.15
Jeff Stutz named incoming interim CEO; company recorded $2.6 million in CEO transition costs in Q4
JPMorgan Chase said its Board intends to raise the quarterly common stock dividend to $1.65 per share from $1.50 for the third quarter of 2026, subject to later Board approval. The Board also authorized a new $50 billion common share repurchase program effective July 1, 2026, to be used at management's discretion. The Firm's Stress Capital Buffer requirement of 2.5% and its 11.5% CET1 capital ratio requirement remain unchanged, which matters to shareholders because it signals more capital returned to them under current rules.
Intended quarterly dividend of $1.65 per share, up from $1.50, for the third quarter of 2026
New $50 billion common share repurchase program effective July 1, 2026
Stress Capital Buffer requirement of 2.5% unchanged through September 30, 2027
Standardized CET1 capital ratio requirement including buffers remains 11.5%
Freshpet said co-founder and President Scott Morris will retire effective October 20, 2026, and will serve as an advisor for 18 months afterward. Chief Operating Officer Nicola Baty will take on the additional role of President on the Separation Date.
Scott Morris retires effective October 20, 2026, and is paid base salary until then
Morris becomes an advisor for 18 months at bi-weekly gross payments of $38,904
Nicola Baty, COO since September 2024, will also become President on the Separation Date
Unvested RSUs vest at separation; PSUs vest pro rata through December 2026 subject to performance metrics
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.